Innova Captab Limited (INNOVACAP) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 1.70K
• Price to Earnings (P/E): 35.5
• Beta (1Y): 1.20
• Revenue Growth: 13.89%
• EPS Growth: 17.32%
• Country: IN
• Employees: 1,600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 5.42
• Shares Outstanding: 57,224,930
• 10 Day Avg. Volume: 1,138
• 30 Day Avg. Volume: 1,704
• PEG Ratio: 1.98
• Price to Book (P/B): 5.33
• Price to Sales (P/S): 4.11
• P/FCF Ratio: -47.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹935.00
• Price Target Upside: 16.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ₹935.00 ▲(16.11% Upside)

Innova Captab Limited has a strong financial performance with robust revenue growth and profitability margins. However, technical indicators suggest bearish momentum, and the valuation appears high without a dividend yield. Improving cash flow generation is crucial for enhancing financial resilience.

Innova Captab Limited Business Overview & Revenue Model

Company Description

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also involved in the development, manufacture, and distribution of generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial, erectile dysfunction, anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through its network of distributors and pharmacies, as well as online through various e-commerce pharmacy sites. The company was incorporated in 2005 and is based in Panchkula, India.

How the Company Makes Money

Innova Captab Limited generates revenue through the sale of its pharmaceutical products. The company's key revenue streams include selling generic medications and over-the-counter drugs to pharmacies, hospitals, and healthcare providers. Additionally, Innova Captab may engage in partnerships with other pharmaceutical firms to expand its product offerings and increase distribution channels. Revenue is also potentially derived from exporting its products to international markets, capitalizing on the global demand for affordable generic medicines. Factors such as regulatory approvals, production capacity, and market expansion strategies significantly contribute to the company's earnings.

Innova Captab Limited Financial Statement Overview

Summary

Innova Captab Limited showcases a strong financial trajectory with impressive revenue growth and improving profitability margins. The balance sheet is robust with a solid equity position and effective debt management. However, cash flow generation from operations presents challenges, necessitating a focus on improving free cash flow.

Income Statement

Innova Captab Limited has demonstrated strong revenue growth, with a consistent increase in Total Revenue from 2020 to 2025. The Gross Profit Margin has improved significantly, reaching 34.52% in 2025 from 23.53% in 2020, indicating enhanced efficiency in production and cost management. The Net Profit Margin has also shown an upward trend, reaching 10.31% in 2025. Both EBIT and EBITDA margins have improved, highlighting robust operating performance. However, the company should focus on maintaining these margins to ensure sustained profitability.

Balance Sheet

The Balance Sheet of Innova Captab Limited reveals a strong equity base with Stockholders' Equity growing substantially over the years, enhancing the Equity Ratio to 60.71% in 2025. The Debt-to-Equity Ratio stands at 0.35 in 2025, which is favorable and indicates prudent leverage management. Return on Equity (ROE) has improved to 13.37% in 2025, reflecting effective use of equity to generate profits. The company needs to ensure continued focus on debt management to maintain financial stability.

Cash Flow

Innova Captab Limited's cash flow performance shows a mixed picture. The Operating Cash Flow to Net Income Ratio has declined over the years, reaching 0.50 in 2025, indicating a need to enhance cash generation from operations. The Free Cash Flow has been negative in recent years, although it has improved from 2024 to 2025. The company should prioritize improving its Free Cash Flow to ensure long-term financial health and flexibility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.01B	12.44B	10.77B	9.26B	8.00B	4.10B
Gross Profit	4.65B	4.30B	3.42B	2.35B	1.73B	611.45M
EBITDA	2.03B	1.86B	1.67B	1.23B	987.68M	558.57M
Net Income	1.30B	1.28B	943.45M	679.54M	639.53M	345.00M
Balance Sheet
Total Assets	0.00	15.80B	13.21B	10.19B	5.75B	3.70B
Cash, Cash Equivalents and Short-Term Investments	652.81M	652.81M	840.92M	70.25M	8.75M	47.95M
Total Debt	0.00	3.38B	2.45B	2.37B	1.99B	454.97M
Total Liabilities	-9.59B	6.21B	4.90B	6.93B	3.67B	2.25B
Stockholders Equity	9.59B	9.59B	8.31B	2.77B	2.09B	1.45B
Cash Flow
Free Cash Flow	0.00	-1.09B	-1.41B	-118.67M	-209.85M	228.33M
Operating Cash Flow	0.00	638.44M	1.46B	671.24M	588.98M	415.66M
Investing Cash Flow	0.00	-1.52B	-4.99B	-908.43M	-1.88B	-196.68M
Financing Cash Flow	0.00	915.33M	3.61B	270.92M	1.25B	-193.36M

Innova Captab Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 805.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INNOVACAP, the sentiment is Negative. The current price of 805.3 is below the 20-day moving average (MA) of 841.67, below the 50-day MA of 874.36, and below the 200-day MA of 894.76, indicating a bearish trend. The MACD of -14.32 indicates Positive momentum. The RSI at 34.77 is Neutral, neither overbought nor oversold. The STOCH value of 10.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INNOVACAP.

Innova Captab Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	69 Neutral	₹6.06B	11.28	―	―	9.15%	88.32%
INNOVACAP	65 Neutral	―	35.50	―	―	13.89%	17.32%
BALAXI	64 Neutral	₹454.03M	11.33	―	―	―	―
BALPHARMA	60 Neutral	₹1.28B	15.11	―	1.50%	-14.16%	10.85%
BIOFILCHEM	52 Neutral	₹639.23M	22.83	―	―	-31.82%	341.44%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Innova Captab Limited Corporate Events

Innova Captab’s Baddi Plant Passes UK-MHRA Inspection

Innova Captab Limited has successfully completed an inspection of its cephalosporin plant in Baddi, Himachal Pradesh, by the United Kingdom Medicines and Healthcare products Regulatory Agency (UK-MHRA) with no critical or major observations. This successful inspection enhances the company’s credibility and compliance with international standards, potentially strengthening its market position and reassuring stakeholders of its commitment to quality and regulatory adherence.